ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > PMN 310 Clinical Trial

<< Previous

Bullboard Posts

Next >>

Comment by bball67on Oct 19, 2022 5:44pm

164 Views

Post# 35034869

RE:RE:PMN 310 Clinical Trial

Farmer, you don't think they forgot all about getting people to participate in a trial do you? You seem to think they can't recruit people to participate until they file IND, where did you get that? I think that is wrong. You ask potential patients "are you willing to participate in a potential clinical trial of an Alzheimer's drug". Would you be surprised if the Company has a plan and goal to be dosing in January or February? Isn't that what they should be doing.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China